In early May 2026, Pfizer reported first-quarter revenue of US$14.45 billion and net income of US$2.69 billion, with earnings per share easing slightly year on year while the company reaffirmed full-year 2026 revenue guidance of US$59.5 billion to US$62.5 billion and filed an US$8.42 billion employee share offering shelf registration.
At the same time, Pfizer advanced its oncology franchise with positive Phase 3 data for multiple myeloma drug ELREXFIO and secured the first-ever FDA approval of a PROTAC therapy, VEPPANU, while also extending VYNDAMAX patent protection in the US to 2031 through settlements with several generic manufacturers.
We’ll now examine how Pfizer’s earnings beat and reaffirmed 2026 guidance affect the existing investment narrative around its pipeline-driven transition.
Find 44 companies with promising cash flow potential yet trading below their fair value.
Pfizer Investment Narrative Recap
To own Pfizer today, you need to believe its pivot from COVID windfalls to a broader, oncology-led portfolio and obesity pipeline can offset looming patent expirations and pricing pressure. The latest quarter’s revenue beat and reaffirmed 2026 guidance support that transition narrative in the near term, but rising R&D spend and the patent cliff for drugs like Ibrance and Eliquis remain the key risk that could challenge earnings resilience.
Among the recent updates, the settlements extending VYNDAMAX patent protection in the US to 2031 look especially important. By helping stabilize a meaningful cardiology revenue stream beyond 2028, they give Pfizer a little more breathing room as it tries to ramp newer launches like ELREXFIO and VEPPANU into larger franchises ahead of the main patent expiries and ongoing drug pricing reforms.
Yet even with these positives, investors should be aware that the upcoming loss of exclusivity on major brands could…
Read the full narrative on Pfizer (it’s free!)
Pfizer’s narrative projects $59.6 billion revenue and $12.8 billion earnings by 2028. This requires a 2.2% yearly revenue decline and about a $2.1 billion earnings increase from $10.7 billion today.
Uncover how Pfizer’s forecasts yield a $29.08 fair value, a 10% upside to its current price.
Exploring Other Perspectives 
PFE 1-Year Stock Price Chart
Before this earnings beat, the most pessimistic analysts were modeling Pfizer’s revenue to fall toward about US$49.0 billion by 2029, so if you worry about patent expiries outpacing new launches, their caution highlights how far opinions can diverge and why it can pay to compare several viewpoints before deciding how this latest quarter might shift the balance.
Explore 23 other fair value estimates on Pfizer – why the stock might be worth 10% less than the current price!
Reach Your Own Conclusion
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
Interested In Other Possibilities?
Right now could be the best entry point. These picks are fresh from our daily scans. Don’t delay:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include PFE.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com